Pinpoint Therapeutics Raises $1 Million Seed Round Led by Kairos Ventures

On February 11, 2020 Pinpoint Therapeutics, Inc. ("Pinpoint"), a privately held biopharmaceutical company focused on the development of novel autophagy inhibitors to treat cancer, reported that it has raised $1 million in debt financing led by Kairos Ventures of Beverly Hills, California (Press release, Pinpoint Therapeutics, FEB 11, 2020, View Source [SID1234554193]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pinpoint was founded by researchers Ravi K. Amaravadi, M.D., and Jeffrey D. Winkler, Ph.D., from the University of Pennsylvania’s Abramson Cancer Center and the Department of Chemistry, to develop new autophagy inhibitors for cancer treatments. Autophagy is a well-established mechanism of cancer cell survival and drug resistance. Pinpoint’s novel compounds target a recently discovered enzyme in the autophagy pathway called PPT1, which is highly expressed across most cancers. These inhibitors could be applied to a broad range of cancers alone or in combination with other treatments to overcome therapy resistance. Pinpoint will develop first-in-class autophagy inhibitors into clinical drugs for testing in a range of treatment-refractory cancers.

"This initial round of financing will allow us to develop a new approach to drugging autophagy, which until now seemed difficult to target in cancer. The activity of PPT1 inhibitors in cancer models has not been seen before in the autophagy space," said Christian Peters, M.D., Ph.D., Chief Executive Officer of Pinpoint.

"Pinpoint has developed best-in-class compounds with unprecedented therapeutic potential and we are thrilled to support their efforts as they develop these novel drug-candidates for treatment of colon cancer, pancreatic cancer, melanoma, and other major unmet needs in oncology," said Jim Demetriades, founder and Managing Partner of Kairos Ventures.

BerGenBio ASA: Results For The Fourth Quarter and Full Year 2019

On February 11, 2020 BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, reported its results for the fourth quarter and full year 2019 (Press release, BerGenBio, FEB 11, 2020, View Source [SID1234554192]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation and live webcast by the Company’s management will take place today at 10.00 am CET in Oslo, please see below for details.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "I am pleased to report on another eventful quarter for BerGenBio. During the period bemcentinib was approved for Fast Track Designation by the USA FDA for AML, and we continued to see encouraging data emerge from our ongoing phase II clinical trials with bemcentinib. The primary endpoint was met in our lung cancer trail in combination with Merck’s checkpoint inhibitor Keytruda. We were particularly pleased to see responses among patients for whom checkpoint inhibitors would not usually be expected to be effective. In January we reported achieving a similar endpoint in NSCLC patients who had previously relapsed on checkpoint inhibitors. Looking forward, we anticipate reporting clinical and translational data updates at medical conferences, later in the year. In January we closed a PIPE funding providing an additional NOK 220m, subject to EGM approval, such that the Company is well-financed well beyond current milestones."

Operational Highlights – fourth quarter and full year 2019

Bemcentinib met primary endpoint in first cohort of Phase II NSCLC study in combination with KEYTRUDA
Primary endpoint, Overall Response Rate, was been met in predominantly PD-L1 negative/low patients
Secondary endpoint, median Progression Free Survival, exceeds expectations in AXL positive patients
Data was presented at Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting on 8 November 2019
Preliminary clinical data from Phase II combination trial of bemcentinib and LDAC in elderly AML patients at ASH (Free ASH Whitepaper) 2019
Phase II trial data showed bemcentinib in combination with low-dose cytarabine (LDAC) in elderly AML patients unfit for intensive therapy is well tolerated and shows promising efficacy
Long duration of response (>9.9 mo., still maturing) with 50% complete response (CR/Cri) in 6 evaluable newly diagnosed patients receiving the bemcentinib-LDAC combination
Clinical benefit demonstrated in >2L relapsed and refractory AML patients with 1 CR/CRi and 3 SD out of 6 evaluable patients
Data presented in a poster presentation at the 61st Annual American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting, on 7-10 December in Orlando, Florida.
U.S. Food and Drug Administration (FDA) approved Fast Track Designation for bemcentinib for the treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed.
With this Fast Track designation, BGB is eligible for:

More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval
Eligibility for Accelerated Approval and Priority Review
Clinical trial updates were presented at several major cancer scientific congresses and consistently confirm that NSCLC and AML are the optimal target indications
Phase II development programme read-outs according to plan
AML bemcentinib + LDAC: readouts at American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and European Haematology Association (EHA) (Free EHA Whitepaper)
NSCLC bemcentinib + KEYTRUDA: readouts at ASCO (Free ASCO Whitepaper), World Conference on Lung Cancer (WCLC), European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper), The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)
Proprietary composite AXL tumour-immune (cAXL) score developed to identify & diagnose patients that show durable benefit
Completed Phase Ia trial with tilvestamab (BGB149) in healthy volunteers
Continued to build out the organisation with strategic medical, clinical, operational and regulatory hires
Private placement completed in June, raising NOK 74.2 million
Q4 2019 / FY 2019 Financial Highlights

(Figures in brackets = same period 2018 unless otherwise stated)

Revenue amounted to NOK 0.2 million (NOK 2.3 million) for the fourth quarter and NOK 8.9 million (NOK 2.3 million) for the full year 2019
Total operating expenses for the fourth quarter were NOK 59.3 million (NOK 53.2 million) and total operating expenses for the full year 2019 amounted to 213.3 million (NOK 196.9 million)
Research and development expenses accounted for 77% (74%) of total operating expenses in the full year 2019
The operating loss for the quarter came to NOK 59.1 million (NOK 50.9 million) and NOK 204.4 million (NOK 194.5 million) for the full year 2019, reflecting the level of activity related to the clinical trials BerGenBio is conducting
Cash and cash equivalents amounted to NOK 253.6 million at the end of December 2019 (NOK 360.4 million)
Post-period events

Private placement of NOK 219.9 million successful placed through new share allocation

Net proceeds to be used to advance bemcentinib trial programs in AML and NSCLC, manufacturing scale-up of bemcentinib, biomarker and companion diagnostic development, and phase 1b development of tilvestamab.
Presentation and Webcast Details

A presentation by BerGenBio’s senior management team will take place today at 10:00 am CEST at:

Hotel Continental
Stortingsgata 24/26, Oslo

The presentation will be webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.

Medivir Invites to R&D Day on March 2, 2020

On February 11, 2020 Medivir AB (Nasdaq Stockholm: MVIR) reported investors, analysts and the media to an R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET (Press release, Medivir, FEB 11, 2020, View Source [SID1234554191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will, among other things, address new clinical results from the phase Ia study with MIV-818 in liver cancer patients. Members of Medivir’s management team and Professor Jeff Evans, Director of the Institute of Cancer Sciences at the University of Glasgow, will give presentations.

The meeting will be held at Helio GT30, Grev Turegatan 30 in Stockholm, on March 2 at 14:00 to 16:30 CET.

To register now, send an e-mail to: [email protected]

A formal invitation with a full program will be sent out and be available on www.medivir.se.

Warm welcome!

About MIV-818
MIV-818 is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug to benefit patients with HCC and other forms of liver cancer.

Moberg Pharma AB Interim Report October – December 2019

On February 11, 2020 Moberg Pharma AB reported that Interim Report October – December 2019(Press release, Moberg Pharma, FEB 11, 2020, View Source;december-2019-301002541.html [SID1234554190])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Period (Jul-Dec 2019)

Net revenue SEK 50.5 million (15.6) *
EBITDA SEK 38.2 million (-3.0) *
Operating profit (EBIT) SEK 37.0 million (-4.2) *
Profit after tax SEK 28.7 million (-4.7) *
Comprehensive income SEK 28.7 million (499.4)
Diluted earnings per share SEK 1.53 (-0.27) *
Cash and cash equivalents amounted to SEK 64.7 million (919.1)
* All comparative figures refer to continuing operations

Second Quarter (Oct-Dec 2019)

Net revenue SEK 2.7 million (0.0) *
EBITDA SEK -4.2 million (-10.3) *
Operating profit (EBIT) SEK -4.8 million (-9.2) *
Profit after tax SEK -4.0 million (-7.6) *
Comprehensive income SEK -4.0 million (-5.1)
Diluted earnings per share SEK -0.21 (-0.43)
Cash and cash equivalents amounted to SEK 64.7 million (919.1)
The Annual General Meeting on October 30 resolved to extend the company’s financial year to the following period, July 1, 2019 – December 31, 2020. This interim report covers the first six months of the extended fiscal year from July 1, 2019. The comparative figures refer to the abbreviated financial year from January 1, 2019 to June 30, 2019.

Significant Events In The Second Quarter

The Annual General Meeting resolved on October 30 to pay shareholders SEK 46.50 per share through an automatic redemption procedure, in accordance with the Board of Directors’ proposal. Payment was issued in November.

In October, a distribution agreement was signed with DongKoo for MOB-015 in the Republic of Korea.

Mark Beveridge, VP Finance, reassumed responsibility for the finance function and replaced the previous CFO Sarah Hellerfelt.

In December, the topline results were presented from the phase 3 study in North America. MOB-015 met both the primary endpoint and key secondary endpoints. No serious side effects were identified in the study.

Significant Events After The End Of The Second Quarter

Expert analysis confirms the validity of the results from the phase 3 study in North America, including:
i) Treatment with MOB-015 results in a mycological cure that compares favorably to oral onychomycosis drugs and with the added advantage of earlier onset of action;
ii) The proprietary vehicle technology increases the hydration and permeability of the nail plate enabling efficient terbinafine delivery, however it also confounds the assessment of clinical cure and complete cure; and
iii) A likely solution to the problem – a shorter dosing regimen with the potential to deliver superior complete cure rates at 52 weeks.

The Swedish Tax Agency declared that for the redemption of shares in Moberg Pharma for cash proceeds of SEK 46.50 per share, 60 percent the original acquisition cost will represent the redemption shares and 40 percent the remaining ordinary shares.

Statement From The CEO

In December 2019, the results of the first of two clinical studies in the phase 3 program for MOB-015 were presented. The study met both the primary endpoint and key secondary endpoints and no safety issues were identified. The study and subsequent expert analysis showed that MOB-015 has the potential to become the future market leader in onychomycosis. Seventy percent of the patients were fungus free, which is world leading, but increased hydration causes temporary whitening of the nail, which makes the assessment of clinical cure more challenging. A shorter treatment period is a likely solution to the problem of whitening.

The North American study was conducted at 32 clinics in the U.S. and Canada and included a total of 365 patients, where 246 patients were treated with MOB-015 and 119 patients in a control group received the vehicle. At 52 weeks, significantly more MOB-015 patients reached complete cure compared to the vehicle (p=0.019) and mycological cure (fungus-free samples) was reached in 70 percent of the patients, which is significantly higher than has been reported for other topical treatments and compares with, but with an earlier onset of action than, oral terbinafine treatment. In addition, 80 percent of the patients reported an improvement by the first follow-up visit. Provided that the European study also produces positive results, both studies can be used as a basis for product registration.

On the whole, the outcome of the study was surprising, given the clinical cure rate (restoration of normal looking nails) of 4.5 percent was lower than expected based on the high mycological cure. Since the results were made public, the company, in collaboration with leading experts (Key Opinion Leaders, KOL), has analyzed the outcome to validate and better understand the unexpected results. The conclusion of the analysis was that the company’s technology enables high delivery of terbinafine through the nail plate, but its hydrating properties also cause whitening/discoloration in nails. This phenomenon is transient but makes the assessment of clinical cure challenging, which contributed to the low complete cure rate observed. The KOLs as well as the company’s own experts concluded that a higher complete cure is likely to be achieved with a shorter treatment period followed by maintenance dosing. This should maintain high concentrations of terbinafine in the nail tissue, while there is sufficient time for the hydration level to normalize.

From a medical and commercial perspective, a dosing regimen with daily treatment for a maximum of three months, followed by maintenance dosing once weekly, is highly attractive and further improves the target product profile of MOB-015. This is further supported by prescription data from the U.S., which shows that the actual use of existing topical treatments usually lasts between 3 to 4 months, despite intended daily treatment for 48 weeks. The improved product profile with a shorter treatment period also creates key competitive advantages compared to oral terbinafine. If MOB-015 shows the same antifungal effect as oral treatment and can show a high complete cure rate, there would be no medical reason to choose oral treatment over topical treatment.

In the U.S., around 4.5 million onychomycosis prescriptions are written, of which 3 million are for oral terbinafine. Previous launches of novel topical products have not significantly affected oral terbinafine prescriptions. With the improved product profile, MOB-015 will be an attractive alternative to other topical products as well as oral terbinafine.

We are very grateful for the thorough analysis of the key opinion leaders, which not only validated and gave us a better understanding of the reasons for the phase 3 results, but also strengthened our conviction that MOB-015 has the potential to become the future market leader in onychomycosis. Four key licensing agreements are currently in place for MOB-015: in Europe, Japan and Canada, plus the addition of the Republic of Korea in the latest quarter.

The share redemption in November 2019 resulted in an extraordinary payment to our shareholders of SEK 46.50 per share. After the redemption, the company has SEK 65 million in cash reserves and has sufficient funds to finalize the phase 3 studies for MOB-015.

To fully capitalize on MOB-015’s potential, the advantages of a shorter treatment period will have to be documented in another study. The timing of such a study depends on whether the outcome of the EU study provides a basis for product registration. We look forward to the topline data from the EU study by the end of the second quarter and are fully committed to creating the future market leader in onychomycosis. The earlier onset of action and exceptional ability to eliminate the fungus as well as the outlook for a shorter treatment period are very promising

Nuvo Pharmaceuticals™ Announces Fourth Quarter 2019 Results Release Date and Conference Call Details

On February 11, 2020 Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI;OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, reported it expects to release its fourth quarter 2019 financial results before markets open on Tuesday, February 25, 2020 (Press release, Nuvo Pharmaceuticals, FEB 11, 2020, View Source [SID1234554189]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will subsequently hold a conference call that same day, Tuesday, February 25, 2020 at 8:30 a.m. ET, hosted by Jesse Ledger, Nuvo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE:

Tuesday, February 25, 2020

TIME:

8:30 a.m. ET

DIAL-IN NUMBER:

416 764 8688 or 1 888 390 0546

TAPED REPLAY:

416 764 8677 or 1 888 390 0541 / REPLAY PASSCODE: 692181 #

The audio webcast can be accessed at:

View Source